OK, I know my gig is positivity and being upbeat and all that, but for today I thought I’d rant on about something that irks ...

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm ...

The Nation Newspaper Internal Medicine Specialist warns of rare diabetes complication linked to SGLT2 inhibitors ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

The Drug is produced at the USFDA approved facilities of Morepen, which is compliant with global quality standards for ...

Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus, Heart ...

The uptick in the Morepen Labs share came after the company announced that it has rolled out ‘Empamore.’ Empamore is used to ...

Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

Mankind Pharma has launched its affordable generic version empagliflozin in India for diabetes following its patent expiration. The launch follows patent expiration of empagliflozin sold by German ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...